From Financial Modeling Prep: 2025-05-15 03:00:00

SeaStar Medical Holding Corporation, trading as NASDAQ:ICU, reported better-than-expected Q1 2025 earnings with revenue of $293,000 exceeding the estimated $150,000. The company’s QUELIMMUNE therapy drove a four-fold increase in sales compared to the previous quarter, attracting new customers like a children’s medical center. Despite revenue growth, ICU faces financial challenges with a negative P/E ratio of -0.30 and a high price-to-sales ratio of 89.32. The NEUTRALIZE AKI trial, a significant development for ICU, has surpassed 50% enrollment, leading to an interim analysis and a planned webcast to discuss advancements in treating pediatric patients with Acute Kidney Injury (AKI).



Read more at Financial Modeling Prep:: SeaStar Medical Holding Corporation’s Q1 2025 Earn…